NasdaqGM - Delayed Quote USD

Omeros Corporation (OMER)

3.0400 -0.0500 (-1.62%)
At close: April 24 at 4:00 PM EDT
2.9220 -0.12 (-3.88%)
After hours: April 24 at 4:54 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Gregory A. Demopulos M.D. Co-Founder, Chairman, CEO & President 1.79M -- 1959
Mr. Michael A. Jacobsen Chief Accounting Officer, VP of Finance & Treasurer 518.6k -- 1958
Mr. Peter B. Cancelmo J.D. VP, General Counsel & Corporate Secretary 503.24k -- 1979
Dr. Pamela Pierce Palmer M.D., Ph.D. Co-Founder -- -- 1963
Dr. George A. Gaitanaris M.D., Ph.D. Chief Scientific Officer & VP of Science -- -- 1957
Mr. Peter W. Williams Vice President of Human Resources -- -- 1968
Dr. Catherine A. Melfi Ph.D. Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems -- -- 1959
Ms. Nadia Dac VP & Chief Commercial Officer -- -- 1970
Dr. Andreas Grauer M.D. VP & Chief Medical Officer -- -- 1961

Omeros Corporation

The Omeros Building
201 Elliott Avenue West
Seattle, WA 98119
United States
206 676 5000 https://www.omeros.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
198

Description

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Corporate Governance

Omeros Corporation’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 5; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
Omeros Corporation Earnings Call

Related Tickers

VSTM Verastem, Inc.
9.31
-3.12%
 
PHVS Pharvaris N.V.
21.25
-0.19%
 
LYRA Lyra Therapeutics, Inc.
5.23
+0.38%
 
BCRX BioCryst Pharmaceuticals, Inc.
4.2100
-3.88%
 
RGNX REGENXBIO Inc.
16.04
+0.88%
 
FDMT 4D Molecular Therapeutics, Inc.
24.25
-2.26%
 
AUPH Aurinia Pharmaceuticals Inc.
5.03
-1.18%
 
REPL Replimune Group, Inc.
6.33
-1.40%
 
LYEL Lyell Immunopharma, Inc.
2.3000
-5.74%
 
GLYC GlycoMimetics, Inc.
1.8550
+1.09%